BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36899123)

  • 21. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
    Liu L; Zhang J; Zhang X; Cheng P; Liu L; Huang Q; Liu H; Ren S; Wei P; Wang C; Dou C; Chen L; Liu X; Zhang H; Chen M
    J Mol Med (Berl); 2021 Jan; 99(1):107-118. PubMed ID: 33128580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.
    Chi Z; Gao H; Liu H; Wu B; Zhang B; Gu M; Yang W
    Mol Med Rep; 2020 Feb; 21(2):936-944. PubMed ID: 31974619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway.
    Liu J; Lv N; Zhou L; Li Y; Yu L
    Transl Cancer Res; 2020 Feb; 9(2):827-839. PubMed ID: 35117428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.
    Saito K; Zhang Q; Yang H; Yamatani K; Ai T; Ruvolo V; Baran N; Cai T; Ma H; Jacamo R; Kuruvilla V; Imoto J; Kinjo S; Ikeo K; Moriya K; Suzuki K; Miida T; Kim YM; Vellano CP; Andreeff M; Marszalek JR; Tabe Y; Konopleva M
    Blood Adv; 2021 Oct; 5(20):4233-4255. PubMed ID: 34507353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
    Gu S; Hou Y; Dovat K; Dovat S; Song C; Ge Z
    Exp Hematol Oncol; 2023 Feb; 12(1):23. PubMed ID: 36849955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
    Lin L; Que Y; Lu P; Li H; Xiao M; Zhu X; Li D
    Front Pharmacol; 2020; 11():569651. PubMed ID: 33192510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells.
    Zhao H; Jiang Y; Lin F; Zhong M; Tan J; Zhou Y; Liu L; Li G; Deng M; Xu B
    Exp Hematol Oncol; 2022 May; 11(1):29. PubMed ID: 35581670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
    Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide Inhibits Glioma Cells by Increasing Oxidative Stress via the miRNA-338-5p Regulation of Hedgehog Signaling.
    Zhou H; Han L; Wang H; Wei J; Guo Z; Li Z
    Oxid Med Cell Longev; 2020; 2020():7126976. PubMed ID: 32256960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
    Liang S; Zhou X; Cai D; Rodrigues-Lima F; Wang L
    Curr Pharm Des; 2021; 27(26):2990-2998. PubMed ID: 34218775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
    Lu CT; Leong PY; Hou TY; Huang SJ; Hsiao YP; Ko JL
    Phytomedicine; 2018 Dec; 51():39-47. PubMed ID: 30466626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
    Peng J; Li SJ; Fu X; Liu Y; Zhao XL
    Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia.
    Nelson MA; McLaughlin KL; Hagen JT; Coalson HS; Schmidt C; Kassai M; Kew KA; McClung JM; Neufer PD; Brophy P; Vohra NA; Liles D; Cabot MC; Fisher-Wellman KH
    Elife; 2021 Jun; 10():. PubMed ID: 34132194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.